Jon Blaschke, MD
Internal Medicine · Oklahoma City, OKNPI 1417096413
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Medtronic at 34.6% of the total. Reporting peaked in 2019 at $2,611 and has fallen 90.5% since, to $248 in 2025. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Edwards Lifesciences$1K
- Boston Scientific$653
- Amgen$434
- E.r. Squibb & Sons, L.L.C.$260
- Pfizer$250
- plus $1K from 18 others
Across 7 payments — averaging $802.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$6K
What the payments were for
- Travel & lodging$2,85945%
- Food & beverage$3,47355%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 8 | $2,201 |
| Edwards Lifesciences | 14 | $1,213 |
| Boston Scientific | 15 | $653 |
| Amgen | 29 | $434 |
| E.r. Squibb & Sons, L.L.C. | 17 | $260 |
| Pfizer | 21 | $250 |
| Merck | 12 | $196 |
| Heartflow, Inc. | 2 | $161 |
| Novartis | 10 | $153 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $146 |
| Kestra Medical Technology Services, Inc. | 5 | $116 |
| Abbott | 1 | $101 |
| Boehringer Ingelheim | 5 | $89 |
| Actelion Pharmaceuticals US, Inc. | 5 | $87 |
| AstraZeneca | 4 | $64 |
| Philips North America LLC | 4 | $55 |
| Abiomed | 1 | $43 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$400
- Repatha$117
- Confirm Rx$101
How this compares
$6,353 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 545 | $631,211 |
| JardianceEmpagliflozin | 163 | $191,835 |
| EntrestoSacubitril/Valsartan | 169 | $168,388 |
| FarxigaDapagliflozin Propanediol | 121 | $132,652 |
| MultaqDronedarone Hcl | 72 | $86,224 |
| XareltoRivaroxaban | 31 | $35,001 |
| Repatha SureclickEvolocumab | 27 | $14,326 |
| Atorvastatin Calcium | 661 | $11,294 |
| Nebivolol Hcl | 96 | $6,780 |
| Rosuvastatin Calcium | 276 | $6,319 |
| Bisoprolol Fumarate | 193 | $6,160 |
| Metoprolol Succinate | 451 | $5,720 |
| Pravastatin Sodium | 215 | $4,154 |
| Losartan Potassium | 401 | $4,114 |
| Pitavastatin Calcium | 20 | $3,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $250 | $631,211545 claims |
| Boehringer IngelheimJardiance | $89 | $191,835163 claims |
| NovartisEntresto | $153 | $168,388169 claims |
| AstraZenecaFarxiga | $64 | $132,652121 claims |
| Johnson & JohnsonXarelto | $15 | $35,00131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.